Imiquimod; An international update on therapeutic uses in dermatology

International Journal of Dermatology

Volumn 41, Issue 11, 2002, Pages 810-816

  Tyring, Stephen ^a   Conant, Marcus ^b   Marini, Mario ^c   Van Der Meijden, Willem ^d   Washenik, Ken ^e  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; IMIQUIMOD; LIQUID NITROGEN; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; BOWEN DISEASE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONDYLOMA ACUMINATUM; CREAM; CRYOTHERAPY; CYTOKINE RELEASE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EXCISION; FLAKING; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IN VIVO STUDY; KELOID; PAPILLOMA VIRUS; POXVIRUS INFECTION; RECURRENT DISEASE; REVIEW; SCABBING; SKIN EDEMA; SKIN EROSION; SKIN INDURATION; SKIN MANIFESTATION; SKIN TUMOR; VERRUCA VULGARIS; VIRAL SKIN DISEASE; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CARCINOMA; CONDYLOMATA ACUMINATA; DERMATOLOGIC AGENTS; DNA VIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SKIN NEOPLASMS;

EID: 0036857317     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2002.01597.x     Document Type: Review

References (55)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8.
2. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female University students as determined by a PCR-based method. JAMA 1991; 265: 472-477.
3. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993; 20: 274-278.
4. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
5. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000; 163: 503-508.
6. Chuang TY, Perry HO, Kurland LT, et al. Condyloma acuminatum in Rochester, Minn, 1950-1978. II. Anaplasias and unfavorable outcomes. Arch Dermatol 1984; 120: 476-83.
7. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand 1996; 75: 287-290.
8. Simms I, Fairley CK. Epidemiology of genital warts in England and Wales: 1971-94. Genitourin Med 1997; 73: 365-367.
9. Lyttle PH. Surveillance report: Disease trends at New Zealand sexually transmitted disease clinics 1977-93. Genitourin Med 1994; 70: 329-335.
10. Hughes GI, Simms I, Rogers PA, et al. New cases seen at genitourinary medicine clinics: England 1997. Commun Dis Rep CDR Suppl 1998; 8: S1-S11.
11. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: Implications for health care providers. Int J STD AIDS 1996; 7: 197-200.
12. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9: 571-578.
13. Voog E, Lowhagen GB. Follow-up of men with genital papilloma virus infection. Psychosexual aspects. Acta Derm Venereol 1992; 72: 185-186.
14. Filiberti A, Tamburini M, Stefanon B, et al. Psychological aspects of genital human papillomavirus infection: A preliminary report. J Psychosom Obstet Gynaecol 1993; 14: 145-152.
15. Reitano M. Counseling patients with genital warts. Am J Med 1997; 102: 38-43.
16. O'Mahony C, Law C, Gollnick HPM, Marini M. New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS 2001; 12: 565-570.
17. Centres for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1997; 47: RRI.
18. Von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76: 162-168.
19. Reiter M, Testerman T, Miller R, et al. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 1994; 13: 71-76.
20. Gibson S, Imberston L, Wagner T, et al. Cellular requirements for cytokine production in response to the immunomodulators Imiquimod and S-27609. J Interferon Cytokine Res 1995; 15: 537-545.
21. Testerman T, Imberston L, Reiter M, et al. Cytokine induction by immunomodulators and S-270609. J Leukoc Biol 1995; 58: 365-372.
22. Imbertson LM, Bearurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734-739.
23. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21: 1-14.
24. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
25. Harrison C, Jenski L, Voychehovski T, Bernstein D. Modification of immunological responses and clinical disease during Topical R-837 treatment of genital HSV 2 infection. Antiviral Res 1988; 10: 209-223.
26. Sidky Y, Borden E, Weeks C, et al. Inhibition of murine tumour growth by an interferon inducing imidazoquinolinamine. Cancer Res 1992; 52: 3528-3533.
27. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25-30.
28. Garland S, Sellors J, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts; Results of an open-label, multicentre Phase III trial. International J STD AIDS, 2001; 12: 722-729.
29. Gollnick H, Barraso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12: 22-28.
30. Tyring SK, Arany I, Stanley MA, et al. A randomized controlled molecular study of condylomata acuminta clearance during treatment with imiquimod. J Infect Dis 1998; 178: 551-555.
31. Beutner KR, Wiley DJ. Recurrent external genital warts: A literature review. Papillomavirus Report 1997; 8: 69-74.
32. Tyring S. Immune-response modifiers: A new paradigm in the treatment of human papillomavirus. Curr Ther Res Clin Exp 2000; 61: 584-596.
33. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. AIDS 1999; 13: 2397-2404.
34. Conant MA. Immunomodulatory therapy in the management of viral infections in patients with HIV infection. J Am Acad Dermatol 2000; 43: S27-S30.
35. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143: 1026-1031.
36. Tschachler E, Bergstresser PR, Stingl G. HIV-related skin diseases. Lancet 1996; 348: 659-663.
37. Cutler K, Kagen MH, Don PC, et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency syndrome. Acta Derm Venereol 2000; 80: 134-135.
38. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol 2000; 80: 306-307.
39. Schwab RA, Elston DM. Topical imiquimod for recalcitrant facial flat warts. Cutis 2000; 43: 555-556.
40. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus I disease. Arch Dermatol 1999; 135: 1167-1169.
41. Liota E, Smith K, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cut Med Surg 2000; 4: 76-81.
42. Brown CW, O'Donoghue M, Moore R, Tharp M. Recalcitrant molluscum contagiosum in an HIV afflicted male treated successfully with topical imiquimod. Cutis 2000; 65: 363-366.
43. Barba AR, Kapoor S, Berman B. An open label study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001; 7: 20.
44. Hunt MJ, Halliday GM, Weedon D, et al. Regression in basal cell carcinoma: An immunohistochemical analysis. Br J Dermatol 1994; 130: 1-8.
45. Wong DA, Bishop GA, Lowes MA, et al. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol 2000; 143: 91-98.
46. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
47. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813.
48. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in basal cell nevus syndrome patient. Dermatol Surg 2000; 26: 577-579.
49. Hannuksela-Svahn A, Nordal E, Christensen OB. Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream. Acta Derm Venereol 2000; 80: 381-382.
50. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: S23-S24.
51. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. J Am Acad Dermatol 1995; 32: 95-98.
52. Mackenzie-Wood A, Kossard S, De Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-470.
53. Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996; 22: 126-130.
54. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002 (in press).
55. Stockfleth E, Meyer T, Benninghoff B, et al. A randomised, double blind, vehicle controlled study to assess imiquimod 5% cream for the treatment of multiple actinic keratosis. Arch Dermatol 2002 (in press).